Promising combo for High-Risk CLL falls short as trial ends early
NCT ID NCT03514017
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tested a two-drug combination—pembrolizumab and ibrutinib—in people with high-risk chronic lymphocytic leukemia (CLL) who had not yet received treatment. The goal was to see if the drugs could improve the body's immune function and shrink or control the cancer. Only 5 people enrolled before the trial was stopped early, so the results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.